Evaluating telavancin in patients with subarachnoid hemorrhage
Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage
This study is testing how well the antibiotic telavancin gets into the spinal fluid of patients with bleeding in the brain to see if it can help treat tough infections.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | University of Kentucky Academic / other |
| Locations | 1 site (Lexington, Kentucky) |
| Trial ID | NCT06119061 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the penetration of telavancin into the cerebrospinal fluid (CSF) of patients suffering from spontaneous subarachnoid hemorrhage (SAH). It will involve a prospective cohort of critically ill patients aged 18-65 years who have an actively draining ventriculostomy and a Hunt-Hess score of 1-4. Participants will receive telavancin at a dosage of 10mg/kg every 24 hours for three consecutive doses, with serum and CSF samples collected to evaluate drug concentrations. The study seeks to understand the pharmacokinetics of telavancin in this specific patient population, which may help in treating resistant CNS infections.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-65 with spontaneous subarachnoid hemorrhage and an actively draining ventriculostomy.
Not a fit: Patients with a history of hypersensitivity to telavancin, reduced renal function, severe anemia, or those in vulnerable populations such as pregnant individuals or prisoners may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into effective treatment options for bacterial meningitis and ventriculitis in critically ill patients.
How similar studies have performed: While telavancin has shown promise in treating resistant pathogens, this specific evaluation of its CNS penetration in SAH patients is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult aged 18-85 years * Actively draining ventriculostomy Exclusion Criteria: * history of hypersensitivity to telavancin or similar agents * reduced renal function (estimated creatinine clearance \< 50/ml) at the time of consent * severe anemia (hemoglobin \< 7gm/dl) * vulnerable population (pregnant, prisoner) * concomitant antimicrobial therapy
Where this trial is running
Lexington, Kentucky
- University of Kentucky — Lexington, Kentucky, United States (Recruiting)
Study contacts
- Principal investigator: Aaron M Cook, PharmD — University of Kentucky
- Study coordinator: Aaron Cook, PharmD
- Email: amcook0@email.uky.edu
- Phone: 859-323-9258
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.